Larimar Therapeutics (LRMR) PT Lowered to $5 at Baird

June 30, 2026 6:54 AM

Baird analyst Joel Beatty lowered the price target on Larimar Therapeutics (NASDAQ: LRMR) to $5.00 (from $7.00) while maintaining a Outperform rating.

No results found